A recent report from Stat News indicates a decrease in federal lobbying efforts by cannabis industry operators. Notably, Curaleaf, a significant player in the industry, reduced its lobbying spending in Washington, D.C., by almost 40% during the first half of the year compared to its peak spending in 2019. Furthermore, both Columbia Care and Pax Labs took more drastic measures by eliminating their lobbying teams.
The Trump administration is preparing to move cannabis from Schedule I to Schedule III of…
Based on the ruling, products that are legal federally as well as at the state…
The drug’s history of healing and experimentation stretches from ancient China to American counterculture —…
The new partnership will spotlight the stories of people still behind bars for cannabis, support…
Colombia is moving forward with a controversial plan to euthanize dozens of invasive hippos descended…
Imported hashish sustained mountain economies for centuries—until modern legalization and market economics erased it almost…